The FDA has approved Bayer HealthCare Pharmaceuticals Inc.’s Sunharbo (asundexian) 50 mg tablets for use in combination with antiplatelet therapy to reduce the risk of stroke in adults with a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack.
Source:FDA · Read original
Leave a Reply